Marinus Pharmaceuticals (NASDAQ:MRNS – Get Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $10.59 million for the quarter.
Marinus Pharmaceuticals Stock Down 0.2 %
Shares of Marinus Pharmaceuticals stock opened at $0.55 on Tuesday. Marinus Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $10.50. The stock’s 50-day simple moving average is $0.49 and its 200-day simple moving average is $0.85. The company has a market capitalization of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03.
Analyst Ratings Changes
Several research firms have recently weighed in on MRNS. HC Wainwright reissued a “neutral” rating and set a $2.00 target price on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. StockNews.com started coverage on Marinus Pharmaceuticals in a research note on Saturday. They set a “sell” rating on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $4.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $4.79.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Read More
- Five stocks we like better than Marinus Pharmaceuticals
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Finding Hidden Gems: Unconventional Penny Stock Investing
- Best Stocks Under $10.00
- Price Targets on NVIDIA Rise in Front of Earnings
- The Most Important Warren Buffett Stock for Investors: His Own
- Archer Aviation Stock Skids: Mistaking Progress for Bad News?
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
